RxDoctor Payments Data

Robert Staffen, MD

Cardiovascular Disease · Latrobe, PANPI 1669441762

Payments from drug & device makers

$556in general payments, 2019–2025

Across 31 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$132
  • Pfizer$119
  • E.r. Squibb & Sons, L.L.C.$87
  • Amgen$64
  • Boehringer Ingelheim$49
  • Boston Scientific$24
  • plus $80 from 5 others

What the payments were for

  • Food & beverage$556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$556 in reported general payments places this provider in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$118,050
Medicare patients
407
Services billed
1,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban588$690,249
XareltoRivaroxaban244$281,661
Repatha SureclickEvolocumab182$201,206
EntrestoSacubitril/Valsartan53$76,111
JardianceEmpagliflozin23$34,480
Praluent PenAlirocumab31$23,398
FarxigaDapagliflozin Propanediol16$22,893
Metoprolol Succinate676$14,149
Rosuvastatin Calcium703$13,006
Atorvastatin Calcium646$10,615
Ezetimibe232$6,431
Dofetilide16$5,787
Losartan Potassium266$4,179
ClopidogrelClopidogrel Bisulfate220$3,919
Irbesartan159$3,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$690,249588 claims
Johnson & JohnsonXarelto$17$281,661244 claims
NovartisEntresto$132$76,11153 claims
Boehringer IngelheimJardiance$49$34,48023 claims
AstraZenecaFarxiga$16$22,89316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Latrobe

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →